Screen 20shot 202018 08 15 20at 205.01.41 20pm
Zylo 20logo

Zylö Therapeutics

Many products have limited duration-of-effect, requiring constant re-application. Our Patchless Patch solves this, providing a clear-cut marketing advantage

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Greenville, SC, USA
  • Currency USD
  • Founded November 2017
  • Employees 7
  • Incorporation Type C-corp
  • Website zylotherapeutics.com

Company Summary

Our inventors (Albert Einstein College of Medicine) developed the Z-pod(TM) to significantly extend the topical effect of most therapeutic payloads. It is like a dermal patch, but without the cost and hassle of a patch, thereby providing a critical marketing edge to OTC and cosmetic marketers across a range of market segments. We have also harnessed the power of NO w/this technology. 50+ published studies of animal models show efficacy & safety.

Team

  • 526cd4a3 1019 4f87 a6f0 08aaa79d04af
    CEO/Founder/Board Member

    CEO of Lpath, 2005-14, took from
    incubation at SDSU to NASDAQ listing, raised $90M equity, $50M non dilutive capital, partnered with Merck, Pfizer, J&J & Biogen. EVP of WSIG 1994-04, managed portfolio of startups, incl. Endonetics (sold to Medtronic), Mpex (sold to Axcan), DermTech (in revenue ramp-up). UVA (BA), Harvard MBA

  • 2aa9fce3 4ca1 4180 8768 f632de2e41af
    VP BD & strategy

    Harvard MBA
    Goldman Sachs
    Lead producer w/ boutique I-Bank doing M&A of OTC/cosmetic brands

  • Deb2b78d d476 49cc 9719 6b921bcaedb7
    VP Ops & Planning

    Seasoned executive at ARx (including President)
    Received PhD from Duke (Material Sciences)

Advisors

  • Default avatar
    Adam Friedman MD
    Unconfirmed
    Default avatar
    Joshua Nosanchuk MD
    Unconfirmed
  • Default avatar
    Kelvin Davies PhD
    Unconfirmed

Previous Investors